Navigating Pregnancy, Dermatology, and Drug Safety
February 19th 2024Katherine Economy, MD, discusses the challenges and opportunities of treating pregnant patients with dermatologic conditions, emphasizing the importance of comprehensive medication reviews, patient-centered decision-making, and the need for including pregnant patients in clinical trials.
Prescribing Excellence: The Symphony of Dermatology Care with Clinical Pharmacists
February 18th 2024A poster presentation explored the transformative impact of integrating clinical pharmacists into an outpatient dermatology clinic, emphasizing collaborative efforts to enhance patient care and improve outcomes in biologic therapy.
Advancements in Molecular Profiling: Differentiating Skin Diseases Through Non-Invasive Techniques
February 17th 2024Investigators revealed the development of a non-invasive molecular test utilizing gene expression differences in skin diseases such as atopic dermatitis, psoriasis, and mycosis fungoides, with the potential to accurately diagnose and identify super-responders to targeted systemic therapies.
Silver Linings With the Silverbergs: Showcasing Vitiligo and Atopic Dermatitis Research
January 11th 2024Innovative practice pearls for both vitiligo and atopic dermatitis treatment were shared with nearly 200 clinicians to put into practice at the virtual Revolutionizing Vitiligo and Revolutionizing Atopic Dermatitis Conferences.
Exploring the Therapeutic Potential of Lavender Essential Oil in Atopic Dermatitis
January 10th 2024Study findings suggest that Lavandula species, with their historical use in folk medicine, could emerge as valuable additions to AD treatment regimens. However, it's crucial to note that the efficacy of these oils is concentration-dependent.
FDA Accepts Accord BioPharma's BLA for Proposed Ustekinumab Biosimilar DMB-3115
January 4th 2024The BLA submission for DMB-3115 is rooted in phase III multi-regional clinical trials focusing on plaque psoriasis patients. The results demonstrated a high similarity between DMB-3115 and ustekinumab in terms of quality, safety, and efficacy.